Xcout IntelAmylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Subscribe to see Amylyx Pharmaceuticals, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Amylyx Pharmaceuticals, Inc. at a glance
Amylyx Pharmaceuticals, Inc. is a biotechnology company headquartered in Cambridge, United States, founded in 2013. It is publicly listed (AMLX) with a market capitalisation of $3.1B. Xcout tracks 26 named people at Amylyx Pharmaceuticals, Inc., including Justin Klee (Co-CEO & Director). Xcout recorded 145 job postings from Amylyx Pharmaceuticals, Inc. in the last 90 days, naming tools such as NetSuite, Power BI.
Amylyx Pharmaceuticals, Inc. leadership
- Justin KleeCo-CEO & Director
- James FratesChief Financial Officer
- James M FratesChief Financial Officer
- Camille L BedrosianChief Medical Officer
- Gina MazzarielloChief Legal Officer & General Counsel
- Dan MonahanChief Commercial Officer
20 more named people on record for Amylyx Pharmaceuticals, Inc., with roles, board committees and tenure — see the full roster →
Amylyx Pharmaceuticals, Inc. funding rounds on record
The most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Debt | $1.8M | — |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Amylyx Pharmaceuticals, Inc.
Xcout recorded 145 job postings from Amylyx Pharmaceuticals, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
Tools named in Amylyx Pharmaceuticals, Inc.'s job postings
The weekly hiring trend, the roles and locations behind it — see Amylyx Pharmaceuticals, Inc.'s hiring signals →
Hiring vs the trend
Based on 68 job postings in the last 8 weeks (10 Aug – 4 Oct 2026), compared with 158 scale-up healthcare companies.
This describes a hiring pattern — how often Amylyx Pharmaceuticals, Inc.’s job postings ask for AI skills, and how that changed against the previous 8 weeks, ranked among its peers. It says nothing about the company’s products or performance.
Signed-in members see the AI-skill share and its change with peer percentiles, role mix, posting momentum and advertised US pay against the market.
Investors
Tech stack
Amylyx Pharmaceuticals, Inc. competitors
A few of Amylyx Pharmaceuticals, Inc.'s closest competitors — see the full list of competitors and alternatives →
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
ProJenX, Inc. is a clinical-stage biotechnology company founded in 2021 and headquartered in New York City. The firm focuses on neuroscience, developing novel, brain-penetrant therapies targeting biologically defined motor neuron diseases such as ALS. It advances research programs aimed at addressing severe neurodegenerative conditions.
Libra Therapeutics is a biopharmaceutical company headquartered in Del Mar, California, focused on developing novel disease-modifying therapeutics. The company aims to restore cellular balance and improve lysosomal function to halt neurodegeneration in conditions such as amyotrophic lateral sclerosis.
Prilenia Therapeutics is a clinical-stage biotechnology company developing treatments for neurodegenerative and neurodevelopmental disorders. Its lead drug candidate, pridopidine, has been studied in Huntington’s disease and amyotrophic lateral sclerosis (ALS), serving patients with serious neurological conditions.
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.
AZTherapies, Inc. is a private, late-stage clinical biopharmaceutical company founded in 2011 and headquartered in Boston, Massachusetts. The company focuses on developing novel treatments for devastating neurological conditions.
Get Amylyx Pharmaceuticals, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Amylyx Pharmaceuticals, Inc. in Xcout Intel
- 26 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- Weekly hiring history and the mix of roles behind it
- 2 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access